Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

The cancer drug discovery field has placed much emphasis on the identification of novel
and cancer-specific molecular targets. A rich source of such targets for the design of novel …

Inflammation is involved in regulation of cellular events in prostate carcinogenesis through
control of the tumour micro‐environment. A variety of bone marrow‐derived cells, including …

The destruction of proteins via the ubiquitin–proteasome system is a multi-step, complex
process involving polyubiquitination of substrate proteins, followed by proteolytic …

Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are
associated with the development of castration-resistant prostate cancer (CRPC), including …

Proteasomes play a critical role in the fate of proteins that are involved in major cellular
processes, including signal transduction, gene expression, cell cycle, replication …

Inhibition of the ubiquitin-proteasome system (UPS) of protein degradation is a valid anti-
cancer strategy and has led to the approval of bortezomib for the treatment of multiple …

The proteasome inhibitors Bortezomib (BZM) and MG132 trigger cancer cell death via
induction of endoplasmic reticulum (ER) stress and unfolded protein response …

Background: Emerging evidence demonstrates that targeting the tumor proteasome is a
promising strategy for cancer therapy. Objective: This review summarizes recent results from …